[1]
Ahgren, C.; Backro, K.; Bell, F.W.; Cantrell, A.S.; Clemens, M.; Colacino, J.M.; Deeter, J.B.; Engelhardt, J.A.; Hogberg, M.; Jaskunas, S.R.; Johansson, N.G.; Jordan, C.L.; Kasher, J.S.; Kinnick, M.D.; Lind, P.; Lopez, C.; Morin, J.M. Jr.; Muesing, M.A.; Noreen, R.; Oberg, B.; Paget, C.J.; Palkowitz, J.A.; Parrish, C.A.; Pranc, P.; Rippy, M.K.; Rydergard, C.; Sahlberg, C.; Swanson, S.; Ternansky, R.J.; Unge, T.; Vasileff, R.T.; Vrang, L.; West, S.J.; Zhang, H.; Zhou, X.X. The PETT series, a new class of potent nonnucleoside inhibitors of human immunodeficiency virus type 1 reverse transcriptase. Antimicrob. Agents Chemother., 1995, 39(6), 1329-1335.
[2]
Bell, F.W.; Cantrell, A.S.; Högberg, M.; Jaskunas, S.R.; Johansson, N.G.; Jordan, C.L.; Kinnick, M.D.; Lind, P.; Morin, J.M.; Noréen, R. Phenethylthiazolethiourea (PETT) compounds, a new class of HIV-1 reverse transcriptase inhibitors. 1. Synthesis and basic structure-activity relationship studies of PETT analogs. J. Med. Chem., 1995, 38, 4929-4936.
[3]
Cantrell, A.S.; Engelhardt, P.; Hogberg, M.; Jaskunas, S.R.; Johansson, N.G.; Jordan, C.L.; Kangasmetsa, J.; Kinnick, M.D.; Lind, P.; Morin, J.M.; Muesing, M.A.; Noreen, R.; Oberg, B.; Pranc, P.; Sahlberg, C.; Ternansky, R.J.; Vasilef, R.T.; Virang, L.; West, S.J.; Zhang, H. Phenethylthiazolylthiourea (PETT) compounds as a new class of HIV-1 reverse transcriptase inhibitors. 2. Synthesis and further structure activity relationship studies of PETT analogs. J. Med. Chem., 1996, 39, 4261-4274.
[4]
Zhang, H.; Vrang, L.; Backbro, K.; Lind, P.; Sahlberg, C.; Unge, T.; Oberg, B. Inhibition of wild type and mutant reverse transcriptase by the phenyl ethyl thiazolyl thiourea derivatives trovirdine and MSC-127. Antiviral Res., 1995, 28(4), 331-342.
[5]
Uckun, F.M.; Mao, C.; Pendergrass, S.; Maher, D.; Zhu, D.; Tuel-Ahlgren, L.; Venkatachalam, T.K.N. -[2-(1-cyclohexenyl)ethyl]-N′-[2-(5-bromo pyridyl)]-thiourea and N′-[2-(1-cyclohexenyl) ethyl]-N′-[2-(5-chloropyridyl)]-thiourea as potent inhibitors of multidrug-resistant human immunodeficiency virus-1. Bioorg. Med. Chem. Lett., 1999, 9(18), 2721-2726.
[6]
Uckun, F.M.; Mao, C.; Pendergrass, S.; Maher, D.; Zhu, D.; Tuel-Ahlgren, L.; Venkatachalam, T.K.N. ′-[2-(2-thiophene)ethyl]-N′-[2-(5-bromopyridyl)] thiourea as a potent inhibitor of nni-resistant and multidrug-resistant human immunodeficiency virus-1. Bioorg. Med. Chem. Lett., 1999, 9(24), 3411-3416.
[7]
Uckun, F.M.; Mao, C.; Pendergrass, S.; Maher, D.; Zhu, D.; Tuel-Ahlgren, L.; Venkatachalam, T.K.N. ′-[2-(4-methylphenyl)ethyl]-N′-[2-(5-bromo pyridyl)]- thiourea as a potent inhibitor of NNI resistant and multidrug-resistant human immunodeficiency virus-1. Antivir. Chem. Chemother., 2000, 11(2), 135-140.
[8]
Venkatachalam, T.K.; Sudbeck, E.A.; Mao, C.; Uckun, F.M. Stereochemistry of halopyridyl and thiazolyl thiourea compounds is a major determinant of their potency as nonnucleoside inhibitors of HIV-1 reverse transcriptase. Bioorg. Med. Chem. Lett., 2000, 10(18), 2071-2074.
[9]
Hunter, R.; Younis, Y.; Muhanji, C.I.; Curtin, T.L.; Naidoo, K.J.; Petersen, M.; Bailey, C.M.; Basavapathruni, A.; Anderson, K.S. C-2-aryl O-substituted HI-236 derivatives as non-nucleoside HIV-1 reverse-transcriptase inhibitors. Bioorg. Med. Chem., 2008, 16, 10270-10280.
[10]
Patel, R.B.; Chikhalia, K.H.; Pannecouque, C.; de Clercq, E. Synthesis of novel PETT analogues: 3,4-Dimethoxy phenyl ethyl-1,3,5-triazinyl thiourea derivatives and their antibacterial and anti-HIV studies. J. Braz. Chem. Soc., 2007, 18, 312-321.
[11]
Tatar, E.; Kucukguzel, S.G.; Karakus, S.; Clercq, E.D.; Andrei, G.; Snoeck, R.; Pannecouque, C.; Okllu, S.K.; Unubol, N.; Kocagoz, T.; Kalayci, S.; Sahin, F.; Kucukguzei, I. Synthesis and biological evaluation of some new 1,3,4-thiadiazole and 1,2,4-triazole derivatives from L-methionine as antituberculosis and antiviral agents. Marmara Pharm. J., 2015, 19, 88-102.
[13]
De Clercq, E.; Descamps, J.; Verhelst, G.; Walker, R.T.; Jones, A.S.; Torrence, P.F.; Shugar, D. Comparative efficacy of antiherpes drugs against different strains of herpes simplex virus. J. Infect. Dis., 1980, 141, 563-574.
[14]
De Clercq, E. Antiviral and antimetabolic activities of neplanocins. Antimicrob. Agents Chemother., 1985, 28, 84-89.
[15]
De Clercq, E.; Holy, A.; Rosenberg, I.; Sakuma, T.; Balzarani, J.; Maudgal, P.C. A novel selective broad-spectrum anti-DNA virus agent. Nature, 1986, 323, 464-467.
[16]
Pannecouque, C.; Daelemans, D.; De Clercq, E. Tetrazolium-based colorimetric assay for the detection of HIV replication inhibitors: Revisited 20 years later. Nat. Protoc., 2008, 3, 427-434.
[17]
Ravichandran, V.; Agrawal, R.K. Predicting anti-HIV activity of PETT derivatives: CoMFA approach. Bioorg. Med. Chem. Lett., 2007, 17, 2197-2202.
[18]
Ravichandran, V.; Prashantha, K.B.R.; Sankar, S.; Agrawal, R.K. Comparative molecular similarity indices analysis for predicting anti-HIV activity of Phenyl Ethyl Thiourea (PET) derivatives. Med. Chem. Res., 2008, 17, 1-11.
63
3
1
1